Form 4 for HBIO HARVARD BIOSCIENCE INC
Accepted 2023-03-15 00:00:00 ET · period of report 2023-03-14 · accession 0000921895-23-000690 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-03-15 | 2023-03-14+ | HBIO | Green James W | CEO, Dir | P - Purchase | $2.63 | +40.0K | 2.87M | +1% | +$105.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-15 | P | A | 20,000 | $2.60 | 2,886,052 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $2.57 to $2.63, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. (F4) Includes (a) the shares and awards described in footnote (2) above, and (b) the shares purchased in the transaction described in footnote (3) above. |
| 2 | Common | Common Stock | 2023-03-14 | P | A | 20,000 | $2.67 | 2,866,052 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $2.61 to $2.70, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes (a) the shares described in footnote (1) above, (b) 353,140 restricted stock units that will vest in three equal installments on December 29, 2023, 2024 and 2025, (c) 104,691 restricted stock units that will vest in two equal installments on December 29, 2023 and 2024, (d) 109,071 restricted stock units that will vest on June 11, 2023, (e) 64,899 restricted stock units that will vest on December 29, 2023, (f) 54,535 restricted stock units that will vest on December 29, 2023, (g) 671,649 restricted stock units with performance based vesting conditions tied to relative total shareholder return and (h) 1,488,067 shares of common stock beneficially owned by the Reporting Person. |